Fluorescence Enhanced Stereotactic Surgery (FESS)
Fluorescence Enhanced Stereotactic Surgery
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
20 participants
Jul 1, 2024
OBSERVATIONAL
Conditions
Summary
Histopathological diagnosis is essential for gliomas, but stereotactic biopsy carries significant risks and can fail to provide diagnostic tissue. This study aims to develop and validate an advanced fiber optic system integrated into a standard Nashold biopsy needle. This system combines 5-ALA fluorescence, Raman spectroscopy, and ultrasound imaging to provide real-time feedback on tumor tissue and blood vessels. The study involves ex-vivo testing on brain tumor tissues (High Grade Glioma) obtained through surgical resection to validate the system's ability to identify tumor margins and vascular structures, aiming to improve biopsy safety and accuracy.
Eligibility
Inclusion Criteria3
- Patient aged 18 years or older
- Patients able to provide the informed consentPresumptive diagnosis of high grade glioma
- Patient whose surgery require the use of 5-ALA as standard of treatment
Exclusion Criteria2
- Patients who are not suitable for surgery
- Patients unable to provide informed consent due to cognitive impairment or other reasons
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07286903